Table 1.
Relationship between PTK7 expression and clinicopathologicdatain invasive ductal breast carcinoma
| Parameters | No. | PTK7 protein expression | P value | rs | ||
|---|---|---|---|---|---|---|
|
| ||||||
| - | + | ++ | ||||
| 79 | 38 (48.1%) | 19 (24.1%) | 22 (27.8%) | |||
| Age (years) | ||||||
| >50 | 47 | 25 (53.2%) | 11 (23.4%) | 11 (23.4%) | 0.232 | 0.136 |
| ≤50 | 32 | 13 (40.6%) | 8 (25.0%) | 11 (34.4%) | ||
| Grade | ||||||
| 1/2 | 54 | 22 (40.7%) | 13 (24.1%) | 19 (35.2%) | 0.025 | -0.251 |
| 3 | 25 | 16 (64.0%) | 6 (24.0%) | 3 (12.0%) | ||
| TNM stage | ||||||
| 1 | 19 | 3 (15.8%) | 6 (31.6%) | 10 (52.6%) | 0.004 | -0.317 |
| 2 | 40 | 23 (57.5%) | 9 (22.5%) | 8 (20.0%) | ||
| 3/4 | 20 | 12 (60.0%) | 4 (20.0%) | 4 (20.0%) | ||
| Lymph node metastasis | ||||||
| No | 32 | 9 (28.1%) | 9 (28.1%) | 14 (43.8%) | 0.002 | -0.351 |
| Yes | 47 | 29 (61.7%) | 10 (21.3%) | 8 (17.0%) | ||
| Molecular subtype | ||||||
| A+B | 43 | 16 (37.2%) | 14 (32.6%) | 13 (30.2%) | 0.195 | -0.147 |
| HER2 | 21 | 14 (66.7%) | 3 (14.3%) | 4 (19.0%) | ||
| Triple | 15 | 8 (53.3%) | 2 (13.3%) | 5 (33.3%) | ||
| ER expression | ||||||
| - | 38 | 24 (63.2%) | 5 (13.2%) | 9 (23.7%) | 0.037 | 0.235 |
| + | 41 | 14 (34.1%) | 14 (34.1%) | 13 (31.7%) | ||
| PR expression | ||||||
| - | 33 | 15 (45.5%) | 7 (21.2%) | 11 (33.3%) | 0.508 | -0.076 |
| + | 46 | 23 (50.0%) | 12 (26.1%) | 11 (23.9%) | ||
| HER2 expression | ||||||
| 0/1+/2+ | 59 | 24 (40.7%) | 16 (27.1%) | 19 (32.2%) | 0.029 | -0.245 |
| 3+ | 20 | 14 (70.0%) | 3 (15.0%) | 3 (15.0%) | ||
| Ki67 expression | ||||||
| <20% | 49 | 17 (34.7%) | 15 (30.6%) | 17 (34.7%) | 0.004 | -0.317 |
| ≥20% | 30 | 21 (70.0%) | 4 (13.3%) | 5 (16.7%) | ||